Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Moreover, I was pleasantly surprised that neither it's up to $2 billion deal with United Biotechnology to develop UBT251 [GLP-1/GIP/GCG triagonist] for the treatment of cardiometabolic diseases ...

Additionally, the company announced an exclusive $1.8 billion license agreement with The United Laboratories for UBT251, a triple receptor agonist targeting GLP-1, GIP, and glucagon. The company also ...

The new drug in question, UBT251, is a next-generation therapy designed to tackle obesity and type 2 diabetes by targeting three key hormones including, GLP-1 and GIP — which regulate appetite and ...

BMO maintains Novo Nordisk stock Outperform rating, $105 target ...